Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
Phase 4
Completed
- Conditions
- Renal Disorder
- Registration Number
- NCT00140985
- Lead Sponsor
- Organon and Co
- Brief Summary
Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 97
Inclusion Criteria
- Males or females at least 18 years of age with non-diabetic proteinuric renal diseases
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method 24h proteinuria
- Secondary Outcome Measures
Name Time Method Changes in the plasma and urinary levels of TGF-beta
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie losartan's antiproteinuric effects in nondiabetic nephropathy?
How does losartan compare to amlodipine in reducing proteinuria among patients with chronic renal disorders?
Are TGFß and VEGF biomarkers predictive of response to losartan in proteinuric kidney diseases?
What adverse events are associated with losartan use in patients with mild to moderate hypertension and renal disease?
What combination therapies or alternative drugs show promise for treating nondiabetic proteinuric nephropathy beyond losartan and amlodipine?